AR
ARCT.US Arcturus Therapeutics Holdings Inc
- Market cap
- USD 241M
- P/E
- -
- P/B
- 1.44x
- ROE
- -46.0%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is ARCT.US undervalued?
Graham numberThe Graham number of Arcturus Therapeutics Holdings Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Arcturus Therapeutics Holdings Inc fundamental analysis
No fundamental analysis for Arcturus Therapeutics Holdings Inc yet.
Arcturus Therapeutics Holdings Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Arcturus Therapeutics Holdings Inc
Arcturus Therapeutics Holdings Inc., a messenger RNA medicines company, focuses on the development of liver and respiratory rare disease therapeutics. Its technology platforms include STARR, a self-amplifying mRNA technology platform, and LUNAR, a lipid-mediated delivery system. The company also develops ARCT-032 (LUNAR-CF), an mRNA therapeutic candidate for cystic fibrosis that is in Phase 2 clinical development; and ARCT-810 (LUNAR-OTC), which is in Phase 2 clinical develo…
Full company profileArcturus Therapeutics Holdings Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Arcturus Therapeutics Holdings Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 20.4M | 13.0M | 15.8M | 20.8M | 9.54M | 12.4M | 206M | 158M | 138M | 67.2M | 29.2M |
| Gross Profit | 20.1M | 12.6M | -1.23M | 20.8M | -46.4M | 12.4M | 206M | 158M | 138M | 64.2M | 28.3M |
| Operating Income | -25.2M | -10.5M | -21.8M | -25.5M | -71.5M | -203M | 12.2M | -78.2M | -95.7M | -75.0M | -86.0M |
| EBITDA | -947K | -10.3M | -20.7M | -24.5M | -70.6M | -200M | 15.2M | -24.2M | -77.4M | -62.8M | -75.8M |
| Net Income | -24.6M | -10.9M | -21.8M | -26.0M | -72.1M | -204M | 9.35M | -29.7M | -80.9M | -65.8M | -77.6M |
| EPS | -6.25 | -3.53 | -2.16 | -2.15 | -3.55 | -7.74 | 0.35 | -1.12 | -3.00 | -2.40 | -2.73 |
| Balance Sheet | |||||||||||
| Total Assets | 51.6M | 52.0M | 44.2M | 82.1M | 476M | 393M | 450M | 429M | 344M | 271M | 215M |
| Total Liabilities | 4.34M | 18.2M | 30.6M | 56.4M | 79.9M | 165M | 180M | 151M | 103M | 57.2M | 46.6M |
| Shareholders' Equity | 47.2M | 33.8M | 13.6M | 25.8M | 397M | 228M | 270M | 279M | 241M | 214M | 169M |
| Cash & Short-term Investments | 50.2M | 48.6M | 36.7M | 71.4M | 463M | 370M | 392M | 292M | 237M | 231M | 185M |
| Total Debt | 133K | - | 9.91M | 20.7M | 20.8M | 69.1M | 94.8M | 30.2M | 28.6M | 25.0M | 21.9M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -19.2M | -460K | -20.8M | -6.45M | -42.9M | -135M | 32.0M | -18.1M | -59.7M | -74.3M | -61.7M |
| Capital Expenditure | 74.0K | 251K | 1.48M | 818K | 1.74M | 3.41M | 7.73M | 2.90M | 648K | 230K | 69.3K |
| Free Cash Flow | -19.3M | -711K | -22.2M | -7.26M | -44.6M | -138M | 24.3M | -21.0M | -60.4M | -74.5M | -61.7M |
| Ratios | |||||||||||
| ROE | -52.1% | -32.3% | -159.7% | -100.8% | -18.2% | -89.2% | 3.5% | -10.7% | -33.6% | -30.7% | -46.0% |
| ROA | -47.7% | -21.0% | -49.3% | -31.6% | -15.1% | -51.8% | 2.1% | -6.9% | -23.5% | -24.3% | -36.0% |
| Net Profit Margin | -120.7% | -83.9% | -138.3% | -125.0% | -756.3% | -1,648.0% | 4.5% | -18.8% | -58.5% | -97.9% | -266.0% |
| Debt to Equity | 0.00x | - | 0.73x | 0.80x | 0.05x | 0.30x | 0.35x | 0.11x | 0.12x | 0.12x | 0.13x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Arcturus Therapeutics Holdings Inc dividends
Arcturus Therapeutics Holdings Inc has not paid dividends in the last 9 fiscal years.
Last stock split: 1:7 on Nov 16, 2017.
Who owns Arcturus Therapeutics Holdings Inc
- Insiders 7.88%
- Institutions 77.22%
- Public & others 14.91%
- Shares outstanding 28.8M
- Free float 26.6M
Top funds holding ARCT.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| ARK Genomic Revolution ETF | 2.98M | 10.49% | +0.58% | Oct 2026 |
| Amova ARK Pstv Chg Innovt P JPY Acc | 1.46M | 5.13% | -3.75% | Sep 2026 |
| Federated Hermes Kaufmann Small Cap A | 924K | 3.25% | -22.15% | Sep 2026 |
| Vanguard MStar Total Stk Mkt Idx Invest | 797K | 2.80% | 0.00% | Sep 2026 |
| Federated Hermes Kaufmann R | 741K | 2.60% | -64.23% | Sep 2026 |
| iShares Russell 2000 ETF | 681K | 2.39% | 0.00% | Oct 2026 |
| Fidelity Small Cap Index | 304K | 1.07% | +3.97% | Aug 2026 |
| Vanguard Explorer Inv | 286K | 1.00% | 0.00% | Sep 2026 |
| iShares Russell 2000 Value ETF | 254K | 0.89% | 0.00% | Oct 2026 |
| Empire Life American Value Cl A | 222K | 0.78% | 0.00% | Sep 2026 |
| iShares Biotechnology ETF | 200K | 0.70% | -4.69% | Oct 2026 |
| JPM Thmtcs Gentc Thrps C2 dist USD | 177K | 0.62% | -0.83% | Sep 2026 |
| ARK Genomic Revolution ETF A USD Acc | 175K | 0.61% | 0.00% | Oct 2026 |
| LVIP FranklinTempletonMltFctSMIDCapEqStd | 175K | 0.61% | 0.00% | Sep 2026 |
| Vanguard Russell 2000 ETF | 156K | 0.55% | +1.03% | Sep 2026 |
| Vanguard Strategic Small-Cap Equity Inv | 155K | 0.55% | -38.78% | Sep 2026 |
| Fidelity Select Biotechnology | 150K | 0.53% | 0.00% | Aug 2026 |
| Schwab US Small-Cap ETF™ | 137K | 0.48% | +0.23% | Oct 2026 |
| Fidelity Extended Market Index | 124K | 0.44% | -15.70% | Sep 2026 |
| Vanguard Strategic Equity Inv | 118K | 0.41% | 0.00% | Sep 2026 |
Top institutions holding ARCT.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Federated Hermes Inc | 3.30M | 11.61% | 0.00% | Jun 2026 |
| ARK Investment Management LLC | 2.90M | 10.20% | +4.77% | Jun 2026 |
| BlackRock Inc | 2.61M | 9.18% | +0.03% | Jun 2026 |
| Sumitomo Mitsui Trust Group Inc | 1.96M | 6.90% | -14.23% | Jun 2026 |
| Amova Asset Management Americas, Inc | 1.96M | 6.89% | -14.35% | Jun 2026 |
| Vanguard Capital Management, LLC | 1.11M | 3.92% | +0.72% | Jun 2026 |
| Two Sigma Investments LLC | 1.09M | 3.83% | +0.86% | Jun 2026 |
| Vanguard Portfolio Management, LLC | 952K | 3.34% | -2.69% | Jun 2026 |
| Geode Capital Management, LLC | 694K | 2.44% | +4.95% | Jun 2026 |
| AQR Capital Management LLC | 675K | 2.37% | +318.54% | Jun 2026 |
| Jacobs Levy Equity Management, Inc. | 648K | 2.28% | +225.83% | Jun 2026 |
| State Street Corp | 570K | 2.00% | +4.73% | Jun 2026 |
| UBS Group AG | 491K | 1.72% | +7.06% | Jun 2026 |
| D. E. Shaw & Co LP | 392K | 1.38% | +55.68% | Jun 2026 |
| Empire Life Investments Inc | 366K | 1.29% | -4.50% | Jun 2026 |
| Hennion & Walsh Asset Management Inc | 346K | 1.22% | +23.79% | Jun 2026 |
| Millennium Management LLC | 337K | 1.18% | -29.58% | Jun 2026 |
| The Goldman Sachs Group Inc | 310K | 1.09% | +55.96% | Jun 2026 |
| BNP Paribas Arbitrage, SA | 262K | 0.92% | +34.35% | Jun 2026 |
| Charles Schwab Investment Management Inc | 232K | 0.81% | +6.99% | Jun 2026 |
Arcturus Therapeutics Holdings Inc company profile
- Company name
- Arcturus Therapeutics Holdings Inc
- Ticker
- ARCT.US
- Exchange
- USA Stocks
- Listed since
- Apr 16, 2020
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 106
- Fiscal year end
- December
- Address
- 10285 Science Center Drive, San Diego, CA, United States, 92121
- Phone
- 858 900 2660
- Website
- arcturusrx.com
About Arcturus Therapeutics Holdings Inc
Arcturus Therapeutics Holdings Inc., a messenger RNA medicines company, focuses on the development of liver and respiratory rare disease therapeutics. Its technology platforms include STARR, a self-amplifying mRNA technology platform, and LUNAR, a lipid-mediated delivery system. The company also develops ARCT-032 (LUNAR-CF), an mRNA therapeutic candidate for cystic fibrosis that is in Phase 2 clinical development; and ARCT-810 (LUNAR-OTC), which is in Phase 2 clinical development to address ornithine transcarbamylase (OTC) deficiency. In addition, it develops KOSTAIVE, a self-amplifying RNA vaccine for COVID-19; ARCT-2138 (LUNAR-FLU), which is in Phase1 clinical trial for the treatment of seasonal influenza; and ARCT-2304 (LUNAR-H5N1) that is in Phase1 clinical trial for the treatment of Pandemic Influenza. Arcturus Therapeutics Holdings Inc. was founded in 2013 and is headquartered in San Diego, California.
Arcturus Therapeutics Holdings Inc management
10- Mr. Joseph E. Payne M.Sc.Founder, President, CEO & Director · born 1972
- Dr. Padmanabh Chivukula Ph.D.Founder, Chief Scientific Officer, COO & Secretary · born 1979
- Mr. Joseph RobertsPrincipal Accounting Officer & Controller · born 1983
- Mr. Lance KurataChief Legal Officer
- Mr. Dennis M. MulroyChief Financial Officer · born 1955
- Ms. Neda SafarzadehVice President and Head of IR/PR & Marketing
- Ms. Natasha O. BowmanChief Human Resources Officer
- Mr. Kevin T. SkolChief Business Officer
- Dr. Igor Smolenov M.D., Ph.D.Chief Development Officer
- Dr. Ye ZhangChief Regulatory & Quality Assurance Officer